442 related articles for article (PubMed ID: 31108184)
1. Optimisation of vancomycin exposure in neonates based on the best level of evidence.
Dao K; Guidi M; André P; Giannoni E; Basterrechea S; Zhao W; Fuchs A; Pfister M; Buclin T; Csajka C
Pharmacol Res; 2020 Apr; 154():104278. PubMed ID: 31108184
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of vancomycin dosing regimens in preterm and term neonates using Monte Carlo simulations.
Mehrotra N; Tang L; Phelps SJ; Meibohm B
Pharmacotherapy; 2012 May; 32(5):408-19. PubMed ID: 22488303
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic modelling and Bayesian estimation-assisted decision tools to optimize vancomycin dosage in neonates: only one piece of the puzzle.
Allegaert K; Flint R; Smits A
Expert Opin Drug Metab Toxicol; 2019 Sep; 15(9):735-749. PubMed ID: 31402708
[No Abstract] [Full Text] [Related]
4. Population pharmacokinetics of vancomycin and AUC-guided dosing in Chinese neonates and young infants.
Chen Y; Wu D; Dong M; Zhu Y; Lu J; Li X; Chen C; Li Z
Eur J Clin Pharmacol; 2018 Jul; 74(7):921-930. PubMed ID: 29602981
[TBL] [Abstract][Full Text] [Related]
5. Assessment of optimal initial dosing regimen with vancomycin pharmacokinetics model in very low birth weight neonates.
Kato H; Hagihara M; Nishiyama N; Koizumi Y; Mikamo H; Matsuura K; Yamagishi Y
J Infect Chemother; 2017 Mar; 23(3):154-160. PubMed ID: 28017667
[TBL] [Abstract][Full Text] [Related]
6. Individualized Empiric Vancomycin Dosing in Neonates Using a Model-Based Approach.
Frymoyer A; Stockmann C; Hersh AL; Goswami S; Keizer RJ
J Pediatric Infect Dis Soc; 2019 May; 8(2):97-104. PubMed ID: 29294072
[TBL] [Abstract][Full Text] [Related]
7. Coagulase negative staphylococcal sepsis in neonates: do we need to adapt vancomycin dose or target?
Padari H; Oselin K; Tasa T; Metsvaht T; Lõivukene K; Lutsar I
BMC Pediatr; 2016 Dec; 16(1):206. PubMed ID: 27931193
[TBL] [Abstract][Full Text] [Related]
8. Determination of vancomycin exposure target and individualised dosing recommendations for neonates: model-informed precision dosing.
Tang Z; Guan J; Li J; Yu Y; Qian M; Cao J; Shuai W; Jiao Z
Int J Antimicrob Agents; 2021 Mar; 57(3):106300. PubMed ID: 33567334
[TBL] [Abstract][Full Text] [Related]
9. Assessment of Vancomycin Pharmacokinetics and Dose Regimen Optimisation in Preterm Neonates.
Mulubwa M; Griesel HA; Mugabo P; Dippenaar R; van Wyk L
Drugs R D; 2020 Jun; 20(2):105-113. PubMed ID: 32266599
[TBL] [Abstract][Full Text] [Related]
10. Vancomycin continuous infusion in neonates: dosing optimisation and therapeutic drug monitoring.
Zhao W; Lopez E; Biran V; Durrmeyer X; Fakhoury M; Jacqz-Aigrain E
Arch Dis Child; 2013 Jun; 98(6):449-53. PubMed ID: 23254142
[TBL] [Abstract][Full Text] [Related]
11. Population Pharmacokinetics and Pharmacodynamic Target Attainment of Vancomycin in Neonates on Extracorporeal Life Support.
Cies JJ; Moore WS; Nichols K; Knoderer CA; Carella DM; Chopra A
Pediatr Crit Care Med; 2017 Oct; 18(10):977-985. PubMed ID: 28650363
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Vancomycin Use in Late-Onset Neonatal Sepsis Using the Area Under the Concentration-Time Curve to the Minimum Inhibitory Concentration ≥400 Target.
Bhongsatiern J; Stockmann C; Roberts JK; Yu T; Korgenski KE; Spigarelli MG; Desai PB; Sherwin CM
Ther Drug Monit; 2015 Dec; 37(6):756-65. PubMed ID: 26562817
[TBL] [Abstract][Full Text] [Related]
13. The Effectiveness of a Vancomycin Dosing Guideline in the Neonatal Intensive Care Unit for Achieving Goal Therapeutic Trough Concentrations.
Reilly AM; Ding MX; Rower JE; Kiser TH
J Clin Pharmacol; 2019 Jul; 59(7):997-1005. PubMed ID: 30776089
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics of vancomycin in term neonates with perinatal asphyxia treated with therapeutic hypothermia.
van der Veer MAA; de Haan TR; Franken LGW; van Hest RM; Groenendaal F; Dijk PH; de Boode WP; Simons S; Dijkman KP; van Straaten HLM; Rijken M; Cools F; Nuytemans DHGM; van Kaam AH; Bijleveld YA; Mathôt RAA;
Br J Clin Pharmacol; 2024 Jun; 90(6):1418-1427. PubMed ID: 38450797
[TBL] [Abstract][Full Text] [Related]
15. Vancomycin Pharmacokinetics Throughout Life: Results from a Pooled Population Analysis and Evaluation of Current Dosing Recommendations.
Colin PJ; Allegaert K; Thomson AH; Touw DJ; Dolton M; de Hoog M; Roberts JA; Adane ED; Yamamoto M; Santos-Buelga D; Martín-Suarez A; Simon N; Taccone FS; Lo YL; Barcia E; Struys MMRF; Eleveld DJ
Clin Pharmacokinet; 2019 Jun; 58(6):767-780. PubMed ID: 30656565
[TBL] [Abstract][Full Text] [Related]
16. Determination of vancomycin pharmacokinetics in neonates to develop practical initial dosing recommendations.
Kim J; Walker SA; Iaboni DC; Walker SE; Elligsen M; Dunn MS; Allen VG; Simor A
Antimicrob Agents Chemother; 2014 May; 58(5):2830-40. PubMed ID: 24614381
[TBL] [Abstract][Full Text] [Related]
17. Evaluation and Development of Vancomycin Dosing Schemes to Meet New AUC/MIC Targets in Intermittent Hemodialysis Using Monte Carlo Simulation Techniques.
Lewis SJ; Mueller BA
J Clin Pharmacol; 2021 Feb; 61(2):211-223. PubMed ID: 32851685
[TBL] [Abstract][Full Text] [Related]
18. The pharmacokinetic/pharmacodynamic rationale for administering vancomycin via continuous infusion.
Waineo MF; Kuhn TC; Brown DL
J Clin Pharm Ther; 2015 Jun; 40(3):259-65. PubMed ID: 25865426
[TBL] [Abstract][Full Text] [Related]
19. Vancomycin is commonly under-dosed in critically ill children and neonates.
Sosnin N; Curtis N; Cranswick N; Chiletti R; Gwee A
Br J Clin Pharmacol; 2019 Nov; 85(11):2591-2598. PubMed ID: 31378957
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics of vancomycin in premature Malaysian neonates: identification of predictors for dosing determination.
Lo YL; van Hasselt JG; Heng SC; Lim CT; Lee TC; Charles BG
Antimicrob Agents Chemother; 2010 Jun; 54(6):2626-32. PubMed ID: 20385872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
